Clinical data | |
---|---|
Trade names | Quviviq |
Other names | Nemorexant; ACT-541468, Daridorexant hydrochloride (USAN US) |
License data |
|
Routes of administration | By mouth[1] |
Drug class | Orexin receptor antagonist |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 62%[1] |
Protein binding | 99.7%[1] |
Metabolism | Extensive (mainly CYP3A4 (89%))[1] |
Onset of action | Tmax: 1–2 hours (delayed by 1.3 hours with food)[1] |
Elimination half-life | 8 hours (6–10 hours)[1][3] |
Duration of action | ~8 hours (50 mg)[3] |
Excretion | Feces: ~57%[1] Urine: ~28%[1] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL |
|
PDB ligand | |
Chemical and physical data | |
Formula | C23H23ClN6O2 |
Molar mass | 450.93 g·mol−1 |
3D model (JSmol) | |
| |
|
Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia.[1][4][5] It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults.[1] The medication is taken by mouth.[1]
Side effects of daridorexant include headache, somnolence, and fatigue.[1] The medication is a dual orexin receptor antagonist (DORA).[6][7][5] It acts as a selective dual antagonist of the orexin receptors OX1 and OX2.[6][7][5] Daridorexant has a relatively short elimination half-life of 8 hours and a time to peak of about 1 to 2 hours.[1][3] It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action.[5]
Daridorexant was approved for medical use in the United States in January 2022[1][8] and became available in May 2022.[9] It was approved in the European Union in April 2022 and was the first orexin receptor antagonist to become available in Europe.[10] The medication is a schedule IV controlled substance in the United States and may have a modest potential for misuse.[1][11][12] Daridorexant is not available in generic formulations.[citation needed] Besides daridorexant, other orexin receptor antagonists including suvorexant and lemborexant have also been introduced.[13]
Daridorexant is indicated for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.[1] The medication has been found to significantly improve latency to persistent sleep (LPS), wake after sleep onset (WASO), and subjective total sleep time (TST) in regulatory clinical trials.[1] At doses of 25 to 50 mg and in terms of treatment–placebo difference, it reduces LPS by 6 to 12 minutes, reduces WASO by 10 to 23 minutes, and increases subjective TST by 10 to 22 minutes.[1] Daridorexant has also been found to improve daytime functioning at a dose of 50 mg but not at 25 mg.[14] It is the first insomnia medication to have been evaluated and shown effectiveness in improving not only nighttime symptoms but also daytime functioning.[15]
Network meta-analyses have found orexin receptor antagonists like suvorexant and lemborexant to be superior in sleep-promoting efficacy to many other sleep aids, such as benzodiazepines, Z-drugs, sedative antihistamines, sedative antidepressants (e.g., trazodone, mirtazapine, amitriptyline), and melatonin receptor agonists.[16][17] However, comparative meta-analyses have not yet included daridorexant, and hence it is unknown how this medication compares to other sleep aids.[16][17] A 2022 network meta-analysis found similar efficacy between different orexin receptor antagonists including daridorexant, although lemborexant may be more effective.[18][17]
Orexin receptor antagonists are not used as first-line treatments for insomnia due to their costs and concerns about possible misuse liability.[16]
Daridorexant is available in the form of 25 and 50 mg oral tablets.[1] It is provided as the salt daridorexant hydrochloride, with each tablet containing 27 or 54 mg of this substance (equivalent to 25 or 50 mg daridorexant).[1]
Daridorexant is contraindicated in people with narcolepsy.[1] It is not recommended in people with severe hepatic impairment, whereas a lower maximum dose is recommended in people with moderate hepatic impairment.[1] Concomitant use of daridorexant with strong CYP3A4 inhibitors and moderate to strong CYP3A4 inducers is not recommended and should be avoided due to unfavorable modification of daridorexant exposure.[1]
Side effects of daridorexant include headache (6% at 25 mg vs. 7% at 50 mg vs. 5% for placebo), somnolence or fatigue (includes somnolence, sedation, fatigue, hypersomnia, and lethargy) (6% at 25 mg vs. 5% at 50 mg vs. 4% for placebo), dizziness (2% at 25 mg vs. 3% at 50 mg vs. 2% for placebo), and nausea (0% at 25 mg vs. 3% at 50 mg vs. 2% for placebo).[1] No residual effects have been found after administration of 25 mg daridorexant in the evening to either young or elderly individuals.[3] However, daridorexant may cause next-morning driving impairment at the start of treatment or in some individuals.[1] Orexin receptor antagonists like daridorexant may have less or no propensity for causing tolerance compared to other sedatives and hypnotics based on animal studies.[5][1] Daridorexant did not produce signs of withdrawal or dependence upon discontinuation in animal studies and clinical trials, and orexin receptor antagonists are not associated with rebound insomnia.[1][3] Loss of sleep-promoting effectiveness occurs rapidly upon discontinuation of daridorexant.[1] Preclinical research has suggested that orexin antagonists may reduce appetite, but daridorexant and other orexin antagonists have not been associated with weight loss in rigorous clinical trials.[13]
Orexin receptor antagonists can affect the reward system and produce drug-liking responses in humans.[19][20][13] Daridorexant at a dose of 50 mg (the maximum recommended dose) showed significantly greater drug liking than placebo but significantly less drug liking than zolpidem (30 mg) and suvorexant (150 mg) in recreational sedative drug users.[1][21] At higher doses of 100 and 150 mg (greater than the recommended maximum dose), drug liking with daridorexant was similar to that with zolpidem (30 mg) and suvorexant (150 mg).[1][21] In other studies, suvorexant showed similar drug liking compared to zolpidem but lower misuse potential on other measures (e.g., overall rate of misuse potential adverse events of 58% for zolpidem and 31% for suvorexant in recreational drug users).[22] No reports indicative of misuse liability were observed in large clinical trials with daridorexant, although these studies excluded participants with history of drug or alcohol misuse.[1][23][21]
There is limited clinical experience with overdose of daridorexant.[1] Overdose of the medication at a dose of up to four times the maximum recommended dose may result in adverse effects including somnolence, muscle weakness, catalepsy-like symptoms, sleep paralysis, attention disturbances, fatigue, headache, and constipation.[1] There is no specific antidote to overdose of daridorexant.[1]
CYP3A4 inhibitors like ranitidine and diltiazem and CYP3A4 inducers like efavirenz can increase and decrease exposure to daridorexant, respectively.[1] Concomitant use of daridorexant with strong CYP3A4 inhibitors or moderate or strong CYP3A4 inducers should be avoided, while it is recommended that the maximum dose of daridorexant be limited with moderate CYP3A4 inhibitors.[1] Gastric pH modifiers like famotidine can decrease peak levels of daridorexant without affecting total exposure.[1] Alcohol and selective serotonin reuptake inhibitors (SSRIs) like citalopram have not shown significant pharmacokinetic interactions with daridorexant.[1] Coadministration of daridorexant with other sedatives like benzodiazepines, opioids, tricyclic antidepressants, and alcohol may increase the risk of central nervous system depression and daytime impairment.[1] Daridorexant has not been found to significantly influence the pharmacokinetics of other drugs including midazolam (CYP3A4 substrate), rosuvastatin (BCRP substrate), and the SSRI citalopram.[1]
Daridorexant acts as a selective dual antagonist of the orexin (hypocretin) receptors OX1 and OX2.[3] The affinities (Ki) of daridorexant for the orexin receptors are 0.47 nM for the OX1 receptor and 0.93 nM for the OX2 receptor.[1] Its Kb values for the human orexin receptors have been reported to be 0.5 nM for the OX1 receptor and 0.8 nM for the OX2 receptor.[5] Hence, daridorexant is approximately equipotent in its antagonism of the orexin receptors.[5] Daridorexant is selective for the orexin receptors over many other targets.[5] In contrast to certain other sedatives and hypnotics, daridorexant is not a benzodiazepine or Z-drug and does not interact with GABA receptors.[5]
The endogenous orexin neuropeptides, orexin A and orexin B, are involved in the regulation of sleep–wake cycles and act to promote wakefulness.[24][13] Deficiency of orexin signaling is thought to be the primary cause of the sleep disorder narcolepsy.[24][13] Disturbances in orexin signaling may also be involved in insomnia.[24] Research suggests that orexin signaling may change with age, and this has been implicated in age-related sleep disturbances.[24] By blocking the actions of orexins and modulating sleep–wake cycles, orexin receptor antagonists like daridorexant reduce wakefulness and improve sleep.[24][13] The sleep-promoting effects of dual orexin receptor antagonists are thought to be mediated specifically by blockade of the OX2 receptor in the lateral hypothalamus.[13] Although narcoleptic symptoms were a theoretical concern during the development of orexin receptor antagonists, this has not been observed in clinical trials of these agents.[24]
The absolute bioavailability of daridorexant is 62%.[1] It reaches peak concentrations within 1 to 2 hours following a dose.[1] Food prolonged the time to peak by 1.3 hours and decreased the peak concentrations by 16%, but did not affect area-under-the-curve concentrations.[1]
The volume of distribution of daridorexant is 31 L.[1] Its plasma protein binding is 99.7%.[1] The plasma-to-blood ratio of daridorexant is 0.64.[1] Daridorexant effectively crosses the blood–brain barrier in animals.[5]
Daridorexant is extensively metabolized primarily by CYP3A4 (89%).[1] Other cytochrome P450 enzymes contribute individually to less than 3% of the clearance of daridorexant.[1]
Daridorexant is eliminated primarily by feces (57%) then by urine (28%).[1] It is excreted mainly in the form of metabolites, with only trace amounts of the parent compound identified.[1]
The medication has an elimination half-life of about 8 hours[1] or of 6 to 10 hours.[3] Its half-life is shorter than that of other orexin receptor antagonists such as suvorexant (12 hours) and lemborexant (~18–55 hours).[3] The relatively short half-life of daridorexant may allow for reduced daytime sedation.[3][13] The duration of action of daridorexant in terms of sedative effects is approximately 8 hours with a 50 mg dose.[3]
Daridorexant is a small-molecule compound.[5] The chemical name of daridorexant is (S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.[25][1] Its molecular formula is C23H23N6O2Cl and its molecular weight is 450.93 g/mol (or 487.38 g/mol for the hydrochloride).[25][1] Daridorexant hydrochloride is a white to light yellowish powder and is very slightly soluble in water.[1]
Daridorexant was patented in 2013[26] and was first described in the scientific literature in 2017.[27][28][29] It was approved for medical use in the United States in January 2022[1][8] and became available in this country in May 2022.[9] On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Quviviq, intended for the treatment of insomnia.[30] On 29 April 2022, daridorexant was authorized for use in the European Union.[10] It was the first orexin receptor antagonist to become available for use in the European Union.[10][31] (The earlier orexin receptor antagonists suvorexant and lemborexant are not available in the European Union.[32][33][34][35]) Regulatory review is also ongoing in Canada and Switzerland and is planned for the United Kingdom.[14][6] Daridorexant was originated by Actelion Pharmaceuticals and was further developed by Idorsia (a new company created from former Actelion drug discovery operations following purchase by Johnson & Johnson in 2017).[6][30]
Daridorexant is a schedule IV controlled substance under the Controlled Substances Act in the United States.[1][11][12]
Daridorexant (Quviviq) was approved for medical use in the European Union in April 2022.[2]
Daridorexant was under development for the treatment of sleep apnea syndrome, but development for this indication was discontinued.[6]